- Home
- RMM vs BDTX Comparison
RMM vs BDTX Comparison
Compare RMM & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- BDTX
- Stock Information
- Founded
- RMM 2019
- BDTX 2014
- Country
- RMM United States
- BDTX United States
- Employees
- RMM N/A
- BDTX N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMM Finance
- BDTX Health Care
- Exchange
- RMM Nasdaq
- BDTX Nasdaq
- Market Cap
- RMM 271.2M
- BDTX 132.5M
- IPO Year
- RMM N/A
- BDTX 2020
- Fundamental
- Price
- RMM $13.55
- BDTX $2.58
- Analyst Decision
- RMM
- BDTX Strong Buy
- Analyst Count
- RMM 0
- BDTX 6
- Target Price
- RMM N/A
- BDTX $14.83
- AVG Volume (30 Days)
- RMM 66.5K
- BDTX 1.3M
- Earning Date
- RMM 01-01-0001
- BDTX 08-05-2025
- Dividend Yield
- RMM 7.33%
- BDTX N/A
- EPS Growth
- RMM N/A
- BDTX N/A
- EPS
- RMM 0.96
- BDTX 0.09
- Revenue
- RMM N/A
- BDTX $70,000,000.00
- Revenue This Year
- RMM N/A
- BDTX N/A
- Revenue Next Year
- RMM N/A
- BDTX N/A
- P/E Ratio
- RMM $15.55
- BDTX $29.29
- Revenue Growth
- RMM N/A
- BDTX N/A
- 52 Week Low
- RMM $12.32
- BDTX $1.20
- 52 Week High
- RMM $16.10
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- RMM 51.90
- BDTX 60.65
- Support Level
- RMM $13.28
- BDTX $2.43
- Resistance Level
- RMM $13.55
- BDTX $2.72
- Average True Range (ATR)
- RMM 0.11
- BDTX 0.18
- MACD
- RMM 0.02
- BDTX -0.00
- Stochastic Oscillator
- RMM 77.81
- BDTX 76.11
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.